Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Vaccines and Diagnostics and the Food Industry Research and Development Institute of Taiwan Awarded US Patents

Premium
Novartis Vaccines and Diagnostics has been awarded US Patent 7,422,861, “Oligonucleotide transfection screening method.”
 
The inventors listed on the patent are Ronald Zuckermann, Christoph Reinhard, Anne Jefferson, and Eric Beausoleil.
 
As stated in its abstract, the patent provides different-sequence peptoids, including lipid- and sterol-conjugated peptoids, that have been found to be effective in the transfection of cells with oligonucleotides. Combinatorial libraries of such peptoids can be screened efficiently in a high-throughput format, and selected peptoids can then be identified post-screening.
 

 
The Food Industry Research and Development Institute of Taiwan has been awarded US Patent 7,422,736, “Somatic pluripotent cells.”
 
The inventor listed on the patent is Shiaw-Min Hwang
 
The patent abstract describes a cultured somatic animal cell having a normal karyotype. The cell develops into an embryoid body when induced in vitro, or develops into a teratoma when introduced into a severe combined immunodeficient mouse. A method of producing such a cell is also discussed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.